A meta-analytic review of polyunsaturated fatty acid compositions in dementia

Journal of Clinical Psychiatry

Volumn 73, Issue 9, 2012, Pages 1245-1254

  Lin, Pao Yen ^a   Chiu, Chih Chiang ^b   Huang, Shih Yi ^b   Su, Kuan Pin ^b,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID;

COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; FATTY ACID BLOOD LEVEL; HUMAN; LIPID COMPOSITION; PREDEMENTIA SYNDROME; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

EID: 84866513402     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11r07546     Document Type: Review

References (67)

1. Cummings JL. Alzheimer's disease. N Engl J Med. 2004;351(1):56-67. PubMed
2. Ferri CP, Prince M, Brayne C, et al; Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366(9503):2112-2117. doi:10.1016/S0140-6736(05)6789-0 PubMed
3. O'Brien JT. Mild cognitive impairment. In: Jacoby R, Oppenheimer C, Dening T, et al, eds. Oxford Textbook of Old Age Psychiatry. 3rd ed. New York, NY: Oxford University Press; 2008:407-415.
4. Bruscoli M, Lovestone S. Is MCI really just early dementia? a systematic review of conversion studies. Int Psychogeriatr. 2004;16(2):129-140. doi:10.1017/S1041610204092 PubMed
5. Fratiglioni L, Strauss E, Qiu C. Epidemiology of the dementia of old age. In: Jacoby R, Oppenheimer C, Dening T, et al, eds. Oxford Textbook of Old Age Psychiatry. 3rd ed. New York, NY: Oxford University Press; 2008: 391-406.
6. Samieri C, Féart C, Letenneur L, et al. Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am J Clin Nutr. 2008;88(3):714-721. PubMed
7. Cole GM, Frautschy SA. DHA may prevent age-related dementia. J Nutr. 2010;140(4):869-874. doi:10.3945/jn.109.13910 PubMed
8. Mucke L, Pitas RE. Food for thought: essential fatty acid protects against neuronal deficits in transgenic mouse model of AD. Neuron. 2004;43(5): 596-599. doi:10.1016/S0896-6273(04)0534-3 PubMed
9. Gomez-Pinilla F. The influences of diet and exercise on mental health through hormesis. Ageing Res Rev. 2008;7(1):49-62. doi:10.1016/j.ar.207.04.03 PubMed
10. Horrobin DF, Bennett CN. Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis: possible candidate genes. Prostaglandins Leukot Essent Fatty Acids. 1999;60(4):217-234. doi:10.1054/plef.19.037 PubMed
11. Su KP, Shen WW, Huang SY. Effects of polyunsaturated fatty acids on psychiatric disorders. Am J Clin Nutr. 2000;72(5):1241. PubMed
12. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids. 2006;75(4-5):259-269. doi:10.1016/j.plefa.206.07.05 PubMed
13. Lukiw WJ, Bazan NG. Survival signalling in Alzheimer's disease. Biochem Soc Trans. 2006;34(pt 6):1277-1282. doi:10.1042/BST034127 PubMed
14. Su KP. Biological mechanism of antidepressant effect of omega-3 fatty acids: how does fish oil act as a "mind-body interface"? Neurosignals. 2009;17(2):144-152. doi:10.159/0198167 PubMed
15. Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry. 2010;68(2):140-147. doi:10.1016/j.biopsych.2010.03.018 PubMed
16. Sanchez-Mejia RO, Mucke L. Phospholipase A2 and arachidonic acid in Alzheimer's disease. Biochim Biophys Acta. 2010;1801(8):784-790. PubMed
17. Lukiw WJ, Bazan NG. Inflammatory, apoptotic, and survival gene signaling in Alzheimer's disease: a review on the bioactivity of neuroprotectin D1 and apoptosis. Mol Neurobiol. 2010;42(1):10-16. doi:10.107/s12035-010-8126-4 PubMed
18. Kalmijn S, Launer LJ, Ott A, et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol. 1997;42(5): 776-782. doi:10.102/ana.410420514 PubMed
19. Barberger-Gateau P, Letenneur L, Deschamps V, et al. Fish, meat, and risk of dementia: cohort study. BMJ. 2002;325(7370):932-933. doi:10.136/bmj.325. 7370.932 PubMed
20. Barberger-Gateau P, Raffaitin C, Letenneur L, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology. 2007;69(20): 1921-1930. doi:10.1212/01.wnl.027816.37320.52 PubMed
21. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003; 60(7):940-946. doi:10.101/archneur.60.7.940 PubMed
22. Huang TL, Zandi PP, Tucker KL, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE ε4. Neurology. 2005;65(9): 1409-1414. doi:10.1212/01.wnl.0183148.34197.2e PubMed
23. Roberts RO, Cerhan JR, Geda YE, et al. Polyunsaturated fatty acids and reduced odds of MCI: the Mayo Clinic Study of Aging. J Alzheimers Dis. 2010;21(3):853-865. PubMed
24. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study, a randomized double-blind trial. Arch Neurol. 2006;63(10):1402- 1408. doi:10.101/archneur.63.10.1402 PubMed
25. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010;304(17):1903-1911. doi:10.101/jama.2010.1510 PubMed
26. Chiu CC, Su KP, Cheng TC, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1538-1544. doi:10.1016/j.pnpbp.208.05.015 PubMed
27. Boston PF, Bennett A, Horrobin DF, et al. Ethyl-EPA in Alzheimer's disease: a pilot study. Prostaglandins Leukot Essent Fatty Acids. 2004;71(5):341-346. doi:10.1016/j.plefa.204.07.01 PubMed
28. Hirai K, Kozuki M, Miyanaga K, et al. Lower levels of eicosapentaenoic acid and the ratio of docosahexaenoic acid to arachidonic acid in sera of patients with multi-infarct dementia. J Clin Biochem Nutr. 2005; 36(3):83-89. doi:10.3164/jcbn.36.83
29. Laurin D, Verreault R, Lindsay J, et al. Omega-3 fatty acids and risk of cognitive impairment and dementia. J Alzheimers Dis. 2003;5(4): 315-322. PubMed
30. Lopez LB, Kritz-Silverstein D, Barrett Connor E. High dietary and plasma levels of the omega-3 fatty acid docosahexaenoic acid are associated with decreased dementia risk: the Rancho Bernardo study. J Nutr Health Aging. 2011;15(1):25-31. doi:10.107/s12603-01-09-5 PubMed
31. Tully AM, Roche HM, Doyle R, et al. Low serum cholesteryl esterdocosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr. 2003;89(4):483-489. doi:10.1079/BJN202804 PubMed
32. Arsenault LN, Matthan N, Scott TM, et al. Validity of estimated dietary eicosapentaenoic acid and docosahexaenoic acid intakes determined by interviewer-administered food frequency questionnaire among older adults with mild-to-moderate cognitive impairment or dementia. Am J Epidemiol. 2009;170(1):95-103. doi:10.1093/aje/kwp089 PubMed
33. Milte CM, Sinn N, Street SJ, et al. Erythrocyte polyunsaturated fatty acid status, memory, cognition and mood in older adults with mild cognitive impairment and healthy controls. Prostaglandins Leukot Essent Fatty Acids. 2011;84(5-6):153-161. PubMed
34. Cherubini A, Andres-Lacueva C, Martin A, et al. Low plasma N-3 fatty acids and dementia in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2007;62(10):1120-1126. doi:10.1093/gerona/62.10.120 PubMed
35. Conquer JA, Tierney MC, Zecevic J, et al. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids. 2000;35(12):1305-1312. doi:10.107/s1745-0-0646-3 PubMed
36. Selley ML. A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease. Neurobiol Aging. 2007;28(12):1834-1839. doi:10.1016/j.neurobiolaging.206.08.03 PubMed
37. Shadish WR, Haddock CK. Combining estimates of effect size. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994:261-281.
38. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. doi:10.136/bmj.315.7109.629 PubMed
39. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-e34. doi:10.1016/j.jclinepi.209.06.06 PubMed
40. Skinner ER, Watt C, Besson JA, et al. Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain. 1993;116(pt 3):717-725. doi:10.1093/brain/16.3.717 PubMed
41. Fraser T, Tayler H, Love S. Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. Neurochem Res. 2010;35(3):503-513. doi:10.107/s1064-09-087-5 PubMed
42. Astarita G, Jung KM, Berchtold NC, et al. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS ONE. 2010;5(9):e12538. doi:10.1371/journal.pone.012538 PubMed
43. Corrigan FM, Horrobin DF, Skinner ER, et al. Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol. 1998;30(2):197-207. doi:10.1016/S1357-2725(97)0125-8 PubMed
44. Kotani S, Sakaguchi E, Warashina S, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res. 2006;56(2):159-164. doi:10.1016/j.neures.206.06.010 PubMed
45. Hashimoto M, Hossain S, Agdul H, et al. Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid β-infused rats relates to the decreases of amyloid β and cholesterol levels in detergent-insoluble membrane fractions. Biochim Biophys Acta. 2005;1738:91-98. PubMed
46. Green KN, Martinez-Coria H, Khashwji H, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-β and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci. 2007;27(16):4385-4395. doi:10.1523/JNEUROSCI.05-07.207 PubMed
47. He K, Song Y, Daviglus ML, et al. Fish consumption and incidence of stroke: a meta-analysis of cohort studies. Stroke. 2004;35(7):1538-1542. doi:10.161/01.STR.0130856.31468.47 PubMed
48. Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54(7): 585-594. doi:10.1016/j.jac.209.02.084 PubMed
49. Chang JP, Chen YT, Su KP. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) in cardiovascular diseases (CVDs) and depression: the missing link? Cardiovasc Psychiatry Neurol. 2009;2009:725310. PubMed
50. Jicha GA, Markesbery WR. Omega-3 fatty acids: potential role in the management of early Alzheimer's disease. Clin Interv Aging. 2010;5: 45-61. doi:10.2147/CIA.S5231 PubMed
51. Calder PC. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie. 2009;91(6):791-795. doi:10.1016/j.biochi.209. 01.08 PubMed
52. Seki H, Tani Y, Arita M. Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat. 2009; 89(3-4):126-130. doi:10.1016/j.prostaglandins.209.03.02 PubMed
53. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr. 2009;28(5):525-542. PubMed
54. Peet M, Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs. 2005;65(8):1051-1059. doi:10.2165/03495-20565080-02 PubMed
55. Bazan NG. Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci. 2006;29(5): 263-271. doi:10.1016/j.tins.206.03.05 PubMed
56. Sijben JW, Calder PC. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Proc Nutr Soc. 2007;66(2): 237-259. doi:10.1017/S0296510705472 PubMed
57. Bazan NG, Colangelo V, Lukiw WJ. Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat. 2002;68-69:197-210. doi:10.1016/S090-6980(02)031-X PubMed
58. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol. 2009;5(3):140-152. PubMed
59. Mischoulon D, Best-Popescu C, Laposata M, et al. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008;18(9):639-645. doi:10.1016/j.euroneuro. 208.04.01 PubMed
60. Mischoulon D, Papakostas GI, Dording CM, et al. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry. 2009;70(12):1636-1644. doi:10.408/JCP.08m04603 PubMed
61. Yehuda S, Rabinovitz S, Carasso RL, et al. The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging. 2002;23(5):843-853. doi:10.1016/S0197-4580(02)074-X PubMed
62. Beydoun MA, Kaufman JS, Satia JA, et al. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. Am J Clin Nutr. 2007;85(4):1103-1111. PubMed
63. Heude B, Ducimetière P, Berr C; EVA Study. Cognitive decline and fatty acid composition of erythrocyte membranes: the EVA Study. Am J Clin Nutr. 2003;77(4):803-808. PubMed
64. Lapillonne A, DeMar JC, Nannegari V, et al. The fatty acid profile of buccal cheek cell phospholipids is a noninvasive marker of long-chain polyunsaturated fatty acid status in piglets. J Nutr. 2002;132(8): 2319-2323. PubMed
65. Connor WE, Neuringer M, Lin DS. Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. J Lipid Res. 1990;31(2):237-247. PubMed
66. Makrides M, Neumann MA, Byard RW, et al. Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am J Clin Nutr. 1994;60(2):189-194. PubMed
67. Stark KD. The percentage of n-3 highly unsaturated fatty acids in total HUFA as a biomarker for omega-3 fatty acid status in tissues. Lipids. 2008;43(1):45-53. doi:10.107/s1745-07-3128-3 PubMed